What the Study Found (In Plain English)
Published in Journal of the American Academy of Dermatology (2026), this phase iii randomized trial evaluating human clinical outcomes investigated: Baricitinib, a Janus kinase inhibitor with an established safety profile across multiple indications, has demonstrated efficacy in the treatment of severe alopecia areata with high maintenance of response during the initial treatment extension period. Key clinical takeaway: Over 152 weeks, patients stably maintained and extended their regrowth across scalp, eyebrows, and eyelashes with continued baricitinib treatment. There were no new safety signals.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Journal of the American Academy of Dermatology, 2026-04-15; Phase III Randomized Trial; Rigor 88/100): Over 152 weeks, patients stably maintained and extended their regrowth across scalp, eyebrows, and eyelashes with continued baricitinib treatment. There were no new safety signals.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.